Author:
Jin Yi,Huang Siwei,Zhou Hongyu,Wang Zhanwang,Zhou Yonghong
Reference34 articles.
1. Head and neck squamous cell carcinoma;Johnson;Nat. Rev. Dis. Primers,2020
2. Cancer statistics for the year 2020: an overview;Ferlay;Int. J. Cancer,2021
3. Head and neck cancer;Chow;N. Engl. J. Med.,2020
4. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019
5. KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献